Meningococcal serogroup B vaccines: Estimating breadth of coverage. Issue 2 (1st February 2017)

• Record Type: Journal Article
• Authors: Donald, Robert G. K.; Hawkins, Julio Cesar; Hao, Li; Liberator, Paul; Jones, Thomas R.; Harris, Shannon L.; Perez, John L.; Eiden, Joseph J.; Jansen, Kathrin U.; Anderson, Annaliesa S.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 2(2017)
• Page Start: 255
• Page End: 265
• Publication Date: 2017-02-01
• Subjects: Neisseria meningitidis -- serogroup B -- bivalent rLP2086 -- Trumenba® -- factor H binding protein -- breadth of coverage; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1264750
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging. While capsular polysaccharide conjugate vaccines have been highly successful in the prevention of disease due to meningococcal serogroups A, C, W, and Y, this approach has not been possible for MenB owing to the poor immunogenicity of the MenB capsular polysaccharide. Vaccines based on outer membrane vesicles have been successful in the prevention of invasive MenB disease caused by the single epidemic strain from which they were derived, but they do not confer broad protection against diverse MenB strains. Thus, alternative approaches to vaccine development have been pursued to identify vaccine antigens that can provide broad protection against the epidemiologic and antigenic diversity of invasive MenB strains. Human factor H binding protein (fHBP) was found to be such an antigen, as it is expressed on nearly all invasive disease strains of MenB and can induce bactericidal responses against diverse MenB strains. A bivalent vaccine (Trumenba®, MenB-FHbp, bivalent rLP2086) composed of equal amounts of 2 fHBP variants from each of the 2 immunologically diverse subfamilies of fHBP (subfamilies A and B) was the first MenB vaccine licensed in the United States under an accelerated approval pathway for prevention of invasive MenB disease. Due to the relatively low incidence of meningococcal disease, demonstration of vaccine efficacy for the purposes of licensure of bivalent rLP2086 was based on vaccine-elicited bactericidal activity as a surrogate marker of efficacy, as measured in vitro by the serum bactericidal assay using human complement. Because bacterial surface proteins such as fHBP are antigenically variable, an important component for evaluation and licensure of bivalent rLP2086 included stringent criteria for assessment of breadth of coverage across antigenically diverse and epidemiologically important MenB strains. This review describes the rigorous approach used to assess broad coverage of bivalent rLP2086. Alternative nonfunctional assays proposed for assessing vaccine coverage are also discussed.